Presentation on innovations in imaging assessment of fibrosis

Lars Johansson (PhD), co-founder and CSO at Antaros Medical, is invited to speak at this year’s Paris NASH meeting on the topic of innovations in imaging assessment of fibrosis. Make sure to tune in to his talk on September 9 @17.15 (CEST) to learn more about how positron emission tomography (PET) and magnetic resonance imaging (MRI) can be applied to understand liver fibrosis.

Paris NASH meeting

The 7th Paris NASH meeting takes place on the 9-10th of September 2021 in Paris, France and virtually. The meeting is organised by leading NASH experts Prof. Arun Sanyal and Prof. Lawrence Serfaty. Key opinion leaders around the world have been invited to discuss current important topics, including NASH disease development and therapeutic advancements.

About metabolic dysfunction-associated steatohepatitis

Metabolic dysfunction-associated steatotic liver disease (MASLD; previously called non-alcoholic fatty liver disease or NAFLD)  affects around 25-30% of the adult population worldwide. The more advanced form of the disease, metabolic dysfunction-associated steatohepatitis (MASH; previously called non-alcoholic steatohepatitis or NASH), is characterised by inflammation and fibrosis and is associated with an increased risk of liver-related mortality. It is crucial to understand disease progression and severity for both clinical management and clinical research. Today, liver biopsy is used for disease stratification but is limited by cost and risks. Imaging biomarkers are emerging as key non-invasive alternatives to assess different aspects of the disease including hepatic steatosis, inflammation and liver fibrosis and cirrhosis as well as down-stream clinical manifestations.

Share on Linkedin Share on Twitter